Navigation Links
Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System

PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc. (NYSE: ALV and SSE: ALIV), today announced the completion of a commercial manufacturing and supply agreement for chemical heat packages, a key component of Alexza's novel single-dose Staccato(R) system. The portable and easy to use single-dose Staccato devices each contain a metal heat package that is chemically heated through a battery- initiated reaction of energetic materials. Alexza single-dose Staccato devices are used in a majority of its current product candidates.

Autoliv will manufacture the chemical heat packages of the single-dose Staccato system. Autoliv is the worldwide leader in automotive safety, and a pioneer in the development of seatbelts and airbags. Autoliv has more than 40 years of experience in developing systems using energetic materials and continues to stand apart as a leader not only in technology but also in its manufacturing techniques.

Mike Ward, President of Autoliv's North American Division, said, "As the largest manufacturer of airbags and seatbelts worldwide, our business focus is saving lives. Partnering with Alexza to manufacture a component of an effective delivery technology for drug therapies based on the use of energetic materials is a natural extension of what we are already doing every day."

"With the completion of this supply agreement with Autoliv, we are executing on our global commercial manufacturing supply strategy. Our strategy includes solidifying supply relationships with leading companies for each of the key device components of our Staccato-based products," said Thomas B. King, President and CEO of Alexza. "Autoliv's quality excellence, cost efficiency and technological leadership in manufacturing with energetic materials makes Autoliv an ideal strategic partner for us, as we advance our product candidates into late-stage development and toward commercialization."

About Autoliv

Autoliv Inc. develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has 80 facilities with approximately 42,000 employees in 28 vehicle-producing countries. In addition, the Company has technical centers in 12 countries around the world, including 21 test tracks, more than any other automotive safety supplier. Sales in 2006 were US $6.2 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on the Stockholm Stock Exchange (SSE: ALIV).

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia.

Safe Harbor Statement

This press release includes forward-looking statements regarding the Company's device technology and product candidates. Any statement describing a product candidate or Alexza's goals, expectations, intentions or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs that are intended to be safe and effective for use as therapeutics. Alexza's forward- looking statements also involve assumptions that, if they do not materialize or prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These statements are based only on facts and factors known by Alexza as of the date hereof. As a result, investors are cautioned not to rely on these forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings "If we do not produce our devices cost effectively, we will never be profitable.", "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.", " If we experience problems with the manufacturers of components of our product candidates, our development programs may be delayed or we may be subject to liability.", and "If we enter into additional strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to terms unfavorable to us.". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering ... dentistry for more than 5 years. A leading cause of emergency room visits, ... treatment is not timely. , Sedation dentistry provides an anxiety-free dental ...
(Date:10/13/2015)... ... ... According to an ESPN report published on October 1, Chicago ... him in the left eye during the first day of practice for the season ... of setbacks, including a knee injury that has interfered with his ability to stay ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... developed valuable new strategies for enrolling and serving insurance consumers who do not ... health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: The ABCs ...
(Date:10/13/2015)... ... October 13, 2015 , ... Just under three months ... eMarketing Concepts began a $1 promotion – effectively offering all of their services for ... within weeks the company was flooded with phone calls from interested buyers. As a ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
(Date:10/12/2015)... N.J. , Oct. 12, 2015  Shareholder rights ... a securities fraud class action complaint was filed in ... Jersey.  The complaint alleges that officers and directors of ... Act of 1934 between September 15, 2015 and October ... about Amicus Therapeutics, business prospects.  Amicus is a biopharmaceutical ...
(Date:10/12/2015)... 12, 2015  Millions of smokers worldwide have used ... of tobacco. An April 2015 study released ... showed electronic cigarettes to be up to 95 percent ... a decade after the technology was first introduced the ... --> --> Palm ...
Breaking Medicine Technology: